Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Drug Resistance, Neoplasm
/ drug effects
Female
Follow-Up Studies
Humans
Isocitrate Dehydrogenase
/ genetics
Leukemia, Myeloid, Acute
/ drug therapy
Male
Middle Aged
Mutation
Neoplasm Recurrence, Local
/ drug therapy
Prognosis
Retrospective Studies
Survival Rate
AML
Enasidenib
IDH
Refractory
Relapse
Journal
Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
02
04
2019
revised:
22
04
2019
accepted:
23
04
2019
pubmed:
6
5
2019
medline:
22
5
2020
entrez:
6
5
2019
Statut:
ppublish
Résumé
Describing the prognosis of sub-groups of acute myeloid leukemia (AML) patients treated in real world with current therapies is becoming increasingly relevant to estimate the benefit that new targeted drugs will bring in the field. This is particularly the case when novel drugs are registered on the basis of non-randomized studies. IDH2 inhibitors have recently emerged as promising drugs in patients with IDH2
Identifiants
pubmed: 31055247
pii: S0145-2126(19)30074-8
doi: 10.1016/j.leukres.2019.04.010
pii:
doi:
Substances chimiques
IDH2 protein, human
EC 1.1.1.41
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
82-87Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.